Venus Remedies

Venus Remedies FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Venus Remedies (VENUSREM.NS) as of Nov 9, 2026 is 116.38 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 179.37 % — a change of -35.11% (lower).

FCF Conversion

116.38 %

YoY

-35.11%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Venus Remedies is 2026 116.38 % . FCF Conversion Rate (FCF/EBITDA) of Venus Remedies was 2025 179.37 % . It decreases by -35.11% lower compared to the previous year.

The Venus Remedies FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
-123.90 INR
Jan 1, 2020
-692.34 INR
Jan 1, 2021
202.20 INR
Jan 1, 2022
67.02 INR
Jan 1, 2023
108.40 INR
Jan 1, 2024
98.16 INR
Jan 1, 2025
179.37 INR
Jan 1, 2026
116.38 INR
The Venus Remedies FCF Conversion history
YEARFCF ConversionYoY
116.38 %-35.11%
179.37 %+82.73%
98.16 %-9.45%
108.40 %+61.74%
67.02 %-66.85%
202.20 %-129.20%
-692.34 %+458.81%
-123.90 %+1.84%
-121.65 %-119.49%
624.27 %-395.98%
-210.92 %-2,951.70%
7.40 %-111.32%
-65.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Venus Remedies Stock analysis

What does Venus Remedies do? Venus Remedies Ltd. manufactures and trades pharmaceutical products, focusing on injectables, tablets, and topical preparations for therapeutic segments including anti-infective, oncology, skin and wound care, and pain management. The company's brands such as Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful, and Nervolize cater to critical care and super specialty markets. Its product portfolio addresses antimicrobial resistance (AMR), oncology, neurology, anticoagulants, and herbal solutions, serving medicine, surgery, neuro, and orthopedics. The firm operates in the Pharmaceutical Formulation segment with three manufacturing facilities. The company sells its pharmaceutical products to healthcare providers and institutions globally, targeting critical care and super specialty segments. Brands like Potentox and Vancoplus Combi are positioned for antimicrobial resistance (AMR) solutions, while Neurotol and Trois serve neurology and orthopedics. Supime and Zydotum focus on pain management and skin care, and Septiloc and Mucomelt address anticoagulants and wound care. Venus Remedies' formulations include injectables, tablets, and topical preparations for diverse therapeutic needs. Venus Remedies Ltd. generates revenue through the sale of its branded pharmaceutical products, including injectables, tablets, and topical preparations. The company's product lines target specific therapy areas such as AMR, oncology, skin and wound care, and pain management, with brands like Ventaful and Nervolize supporting neurology and anticoagulant markets. The firm's global reach in injectable manufacturing and focus on super specialty segments drive its market positioning within the Pharmaceutical Formulation segment. Venus Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Venus Remedies stock

FCF Conversion Rate (FCF/EBITDA) of Venus Remedies is 116.38 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Venus Remedies changed from 179.37 % to 116.38 %, representing a -35.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Venus Remedies since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Venus Remedies with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Venus Remedies

All Key Metrics — Venus Remedies